← Leaderboards
Mark Sorenson
Nirsum Laboratories, Inc.
$4,866,388
Attributed
$9,732,775
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2024–25$5M$3.8M$2.5M$1.3M$0
'24
'25
Funding mix
By agency
NIH$9,732,775 · 1
By mechanism
U01$9,732,775 · 1
Top collaborators
- Nikej Shah2 shared
Most similar at Nirsum Laboratories, Inc.
Same institution · by research overlap
- Nikej Shah$12,588,496
Others in their field
Other Rising Stars on “Acceleration”
- Angee Greer · Ppd Development Lp$82,531,927
- Julia Louise Moore Vogel · Scripps Research Institute, The$32,252,685
- Tim A Bertram · Wake Forest University School Of Medicine$30,163,580
- Nancy Jean Sullivan · Boston University Medical Campus$23,000,000
- Alanna Maguire · Mayo Clinic Rochester$16,353,346
- Michael Hogarth · University Of California, San Diego$15,375,743
Research focus
AccelerationAddictionAffinityAgonistAmendmentAnalogAntagonistAwardBindingBuprenorphineCarcinogenicityCessation Of LifeChemistryClinical DataClinical ResearchClinical TrialsComplexConfidential InformationConsumptionCostCravingCyclic GmpDoseAbstinence
Grant awards (2)
Select Late-Stage CMC, Non-clinical Studies, and Quality Programs to Accelerate NRS-033 Towards Pivotal Studies and Registration in Opioid Use Disorder$4,947,774
U01 · FY2025 · DA
Select Late-Stage CMC, Non-clinical Studies, and Quality Programs to Accelerate NRS-033 Towards Pivotal Studies and Registration in Opioid Use Disorder$4,785,001
U01 · FY2024 · DA